Bora Pharmaceuticals to acquire EISAI
Bora Pharmaceuticals to acquire EISAI’S TAIWAN SUBSIDIARY EISAI TAIWAN’s TAINAN PLANT
Bora Pharmaceuticals Co., Ltd (6472.TWO) and Eisai Co., Ltd.
announced today they have entered into an agreement under which Bora Pharmaceuticals will acquire Eisai 's Tainan facility.
Bora Pharmaceuticals Tainan site.
Lai Ching-te, Vice President of Taiwan, joining the inauguration ceremony to commemorate the successful acquisition of Tainan facility. Source: Bora pharmaceuticals
Please refer to the following articles sourcing from Eisai Co., Ltd. for further information.
Eisai Co., Ltd.
(Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that its Taiwan subsidiary Eisai Taiwan Inc. has entered into an asset sale/purchase agreement to divest its Tainan Plant to Taiwanese pharmaceutical company Bora Corporation (Headquarters: Taipei, Chairman & CEO: Bobby Sheng, “Bora”).
Since commencing operations in 1974, the Tainan Plant has performed its role as a production base that serves emerging countries, particularly in Asia. In recent years, however, the environment surrounding the pharmaceutical industry has been undergoing rapid changes. In order to better and more accurately identify and respond to diversifying customer needs in the pharmaceutical industry, Eisai underwent a transformation in October 2012 that saw its existing production structure, which was based on manufacturing sites managed by region, shift to a globally integrated, unit-based structure organized by product family. Based on a review conducted under the new production structure, which evaluated Eisai’s global supply chain strategy in terms of efficiency and productivity, Eisai and Eisai Taiwan Inc. have decided to divest the Tainan Plant to Bora. Eisai Taiwan Inc. will now move ahead with the procedures necessary to complete the divestment based on local laws and regulations, with the divestment expected to be completed by September 2013. Eisai remains committed to providing high-quality medicines at affordable prices and delivering products that create customer joy, regardless of the challenges posed to the pharmaceutical manufacturing sector by a rapidly changing and increasingly globalized market environment. In doing so, Eisai will continue to make contributions to increase the benefits provided to patients and their families worldwide.
About the Eisai Taiwan Inc.
Tainan Plant Headquartered in Taipei, Eisai Taiwan Inc. is a wholly owned subsidiary of Eisai Co., Ltd. that specializes in the manufacture and sale of pharmaceutical products. Its Tainan Plant, located in Tainan, commenced operations in 1974 as a production base focused mainly on countries in Asia. Eisai Taiwan Inc. has approximately 130 employees, approximately 50 of whom are employed at the Tainan Plant.